Penumbra Inc. (PEN)
NYSE: PEN
· Real-Time Price · USD
297.54
0.22 (0.07%)
At close: May 12, 2025, 3:59 PM
296.50
-0.35%
After-hours: May 12, 2025, 05:51 PM EDT
Penumbra Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|
| Neuro Revenue | 347.74M | 338.71M | 292.63M | 331.69M | 294.33M | 232.45M | 185.53M | 141.41M |
| Neuro Revenue Growth | +2.67% | +15.75% | -11.78% | +12.69% | +26.62% | +25.29% | +31.20% | n/a |
| Peripheral Vascular Revenue | 499.39M | 408.88M | 267.78M | 215.72M | 150.6M | 101.32M | 77.78M | 44.69M |
| Peripheral Vascular Revenue Growth | +22.14% | +52.69% | +24.13% | +43.24% | +48.65% | +30.26% | +74.07% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 153.46M | 147.94M | 139.74M | 139.42M | 141.93M | 130.02M | 125.92M | 127.44M | 123.08M | 115.63M | 108.57M | 114.61M | 110.9M | 113.5M | 94.4M | 90.64M | 79.8M | 76.6M | 76.16M | 59.85M | 74.45M | 74.69M | 69.29M | 67.67M | 61.09M | 61.18M | 55.93M | 54.78M | 54.5M | 51.47M | 45.96M | 44.16M | 42.72M | 41.62M | 37.74M | 35.88M | 33.07M | 29.15M | 26.75M | 26.4M | 19.55M |
| Selling, General, and Administrative Revenue Growth | +3.73% | +5.87% | +0.23% | -1.77% | +9.16% | +3.26% | -1.19% | +3.54% | +6.44% | +6.50% | -5.27% | +3.35% | -2.29% | +20.24% | +4.15% | +13.58% | +4.17% | +0.58% | +27.24% | -19.61% | -0.31% | +7.79% | +2.40% | +10.76% | -0.14% | +9.37% | +2.11% | +0.51% | +5.88% | +11.98% | +4.07% | +3.38% | +2.65% | +10.28% | +5.20% | +8.49% | +13.43% | +8.97% | +1.36% | +35.04% | n/a |
| Research and Development Revenue | 22.08M | 20.01M | 25.2M | 24.94M | 24.63M | 21.94M | 20.96M | 21.54M | 19.99M | 17.96M | 21.32M | 19.56M | 20.56M | 52M | 16.73M | 17.74M | 18.08M | 19.45M | 34.92M | 22.73M | 12.95M | 12.86M | 13.73M | 13.46M | 11.67M | 10.87M | 9.09M | 8.19M | 8.01M | 8.4M | 8.13M | 8.09M | 7.03M | 6.11M | 6.5M | 6.26M | 5M | 5.48M | 4.56M | 4.79M | 3.19M |
| Research and Development Revenue Growth | +10.33% | -20.61% | +1.05% | +1.28% | +12.23% | +4.70% | -2.69% | +7.76% | +11.26% | -15.74% | +9.00% | -4.89% | -60.46% | +210.77% | -5.66% | -1.87% | -7.09% | -44.29% | +53.68% | +75.54% | +0.66% | -6.35% | +2.01% | +15.39% | +7.36% | +19.52% | +10.97% | +2.25% | -4.62% | +3.31% | +0.47% | +15.07% | +15.07% | -5.91% | +3.72% | +25.25% | -8.81% | +20.26% | -4.84% | +50.17% | n/a |